Clinical trials
Prostate Cancer Metastatic Disease clinical trials
Below are recruiting prostate cancer metastatic disease clinical trials, each written for real people, not researchers. We’re tracking 592 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06505356Enrolling by invitation
Genetics and inflammation in prostate cancer stage
This study looks at the connection between genetics, inflammation, and prostate cancer stage. It aims to find markers that may help predict how aggressive the cancer is. You may be eligible if you are newly suspected of having prostate cancer and have not yet started treatment.
KaunasAges 18–100 - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07115446RecruitingPhase 1
Study of HS-20093 and HRS-5041 for advanced prostate cancer
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
ShanghaiAges 18 years+ - NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99 - NCT07198633RecruitingPhase 1/Phase 2
Study of new drugs for advanced prostate cancer
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Chandler, ArizonaAges 18 years+ - NCT05351424Recruiting
Spanish-language cancer care support for breast or prostate radiation
This study tests an educational and communication support program to help Spanish-speaking people stay on track with treatment when they’re getting radiation for non-spread (non-metastatic) breast or prostate cancer. It may help by improving understanding through interpreter-supported visits.
Miami Beach, FloridaAges 18 years+ - NCT05743621RecruitingPhase 1
First TVB-2640 and enzalutamide for metastatic prostate cancer
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
New York, New YorkAges 18 years+ - NCT05790213RecruitingPhase 2
Hormone therapy plus targeted prostate treatment for intermediate cancer
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Chicago, IllinoisAges 18 years+ - NCT05893381RecruitingPhase 2
Targeted PSMA scan plus focused radiation vs radiation alone
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
Cesena, FCAges 18 years+ - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT06236789Recruiting
Ifosfamide for men with advanced prostate cancer
This trial is studying whether the chemotherapy drug ifosfamide (given with mesna to protect the bladder) can help men whose prostate cancer has spread and is no longer controlled by hormone therapy. It is for men who have already tried the chemotherapy docetaxel.
SeoulAges 19 years+ - NCT06484361RecruitingPhase 2
PET/MRI scan for prostate cancer staging before surgery
This trial tests whether a special PET/MRI scan can better see the extent of prostate cancer before surgery. It aims to help doctors plan more precise treatment.
MilanAges 18 years+ - NCT06548672RecruitingPhase 1
Study of BC3195 for advanced or metastatic cancer
This trial tests a new drug called BC3195 in people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective for cancers that express a specific marker called CDH3.
Cleveland, OhioAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06967961Recruiting
Looking for cancer cells that carry two markers in the blood
This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.
ToulouseAges 18 years+ - NCT01050504Recruiting
Donate blood and tissue to study recurrent or metastatic cancers
This study collects and studies blood and, when possible, small tissue samples from people with prostate or bladder/urothelial cancer that has come back or spread. The goal is to better understand these cancers and support future research that may lead to better care.
Seattle, WashingtonAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT06001255RecruitingPhase 2
Testing HS-20093 for advanced prostate and other solid cancers
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
BeijingAges 18 years+ - NCT05183074Recruiting
MRI-guided focused radiation for prostate cancer
This trial tests a newer way to plan and deliver radiation for prostate cancer using real-time MRI guidance. It may help by aiming high-dose treatment precisely while treating nearby disease and (in some cases) limited metastatic spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06583070Recruiting
SABR plus targeted therapy and immunotherapy for advanced kidney cancer
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Beijing, Beijing MunicipalityAges 18–85 - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07455903RecruitingPhase 2
Hormone therapy before surgery for high-risk prostate cancer
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
Miami, FloridaAges 18 years+
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer metastatic disease?
- Yes. Clin2 currently lists 592 recruiting prostate cancer metastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer metastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer metastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.